Tilray Brands
Tilray Brands, Inc. | LinkedIn
  • Tilray (TLRY) has launched its “Take Back Control” platform, which will connect women with free resources on medical cannabis
  • Take Back Control will allow women to make informed decisions about medical cannabis
  • It assists them along their path to discovering how medical cannabis can play a part in their daily healthcare practices
  • Tilray Medical is the recognized global leader in medical cannabis
  • Tilray Stock (TSX:TLRY) is down 3.33 per cent, trading at C$5.23 per share at 12:17 pm ET

Tilray (TLRY) has launched its “Take Back Control” platform, which will connect women with free resources on medical cannabis.

The new platform helps destigmatize the use of medical cannabis in women’s healthcare practices. It connects people with free consultations with healthcare practitioners focusing on women’s health, providing expert advice on medical cannabis.

Take Back Control will allow women to make informed decisions about medical cannabis. It assists them along their path to discovering how medical cannabis can play a part in their daily healthcare practices.

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. It cultivates a wide range of strains to meet patient needs, including indicas, sativas, hybrids, and CBD-rich varieties. Medical cannabis is available in two primary forms: extracts and dried flower.

The company aims to help people take back control of their healthcare choices and treatment. It provides safe and reliable access to a portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios. The company’s production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.


More From The Market Online

Buzz on the Bullboards: Challenges amid inflation and geopolitical tensions

Canadian and U.S. stock markets grapple with a host of challenges, from surging inflation data to escalating tensions in the Middle East.

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.

The Market Online’s Weekly Cannabis Report – April 12, 2024

Canada’s cannabis stock market fluctuated this week thanks to a combination of industry-specific developments and broader market trends